Regenerex Pharma Narrows Loss to $1,000 Amidst Zero Revenue

TL;DR

**RGPX is a pre-revenue biotech burning minimal cash, but its reliance on CEO advances and related-party debt makes it a speculative bet with no clear path to market.**

AI Summary

REGENEREX PHARMA, INC. reported no revenue for the fiscal year ended March 31, 2025, consistent with the prior year. The company incurred a net loss of $1,000 for the fiscal year ended March 31, 2025, a significant improvement from the $10,000 net loss reported for the fiscal year ended March 31, 2024. Key business changes include the purchase of intellectual property on November 15, 2021, for $100,000, which remains a significant asset. The company continues to rely on advances from its CEO and CFO, totaling $1,000 as of March 31, 2025, for operating expenses, down from $10,000 as of March 31, 2024. Risks include the lack of revenue generation and dependence on related party financing, with a $10,000 promissory note from a shareholder outstanding as of March 31, 2025. The strategic outlook involves continued development, as evidenced by the ongoing lease for a plant facility at $1,000 per month, and an office lease at $1,000 per month, indicating operational infrastructure despite minimal financial activity.

Why It Matters

REGENEREX PHARMA's continued lack of revenue and reliance on related-party financing signals significant operational challenges for investors, raising questions about long-term viability and potential dilution. For employees, the minimal activity and financial dependence suggest job insecurity and limited growth prospects. Customers are not directly impacted as the company has no products generating sales. In the broader market, this filing highlights the struggles of early-stage pharmaceutical companies to transition from development to commercialization, especially in a competitive landscape where larger players dominate funding and market share.

Risk Assessment

Risk Level: high — The risk level is high due to REGENEREX PHARMA's complete lack of revenue generation for the fiscal year ended March 31, 2025, and the prior year. The company's operations are heavily dependent on advances from its CEO and CFO, totaling $1,000 as of March 31, 2025, and a $10,000 promissory note from a shareholder, indicating a fragile financial structure with limited independent funding sources.

Analyst Insight

Investors should avoid REGENEREX PHARMA (RGPX) until the company demonstrates a clear path to revenue generation and secures independent, non-related party financing. The current financial state suggests extreme speculative risk with no tangible product sales or market traction.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Key Numbers

• $0 — Revenue (No revenue generated for FY2025 or FY2024, indicating pre-commercial stage.)
• $1,000 — Net Loss (FY2025) (Significantly reduced from $10,000 in FY2024, but still a loss.)
• $10,000 — Net Loss (FY2024) (Prior year's net loss, showing a 90% improvement in loss reduction.)
• $1,000 — CEO/CFO Advances (FY2025) (Total advances from CEO and CFO, down from $10,000 in FY2024, indicating continued reliance on related-party funding.)
• $10,000 — Promissory Note from Shareholder (Outstanding related-party debt as of March 31, 2025, highlighting external financial dependence.)
• $100,000 — Intellectual Property Purchase (Significant asset acquired on November 15, 2021, representing core business focus.)
• $1,000 — Monthly Plant Lease (Ongoing operational expense for a plant facility, indicating development activities.)
• $1,000 — Monthly Office Lease (Ongoing operational expense for an office, maintaining corporate presence.)

Key Players & Entities

• REGENEREX PHARMA, INC. (company) — filer of the 10-K
• $1,000 (dollar_amount) — net loss for FY2025
• $10,000 (dollar_amount) — net loss for FY2024
• $100,000 (dollar_amount) — cost of intellectual property purchased
• CEO (person) — source of advances for operating expenses
• CFO (person) — source of advances for operating expenses
• Shareholder (person) — lender of a $10,000 promissory note
• November 15, 2021 (date) — date of intellectual property purchase
• March 31, 2025 (date) — end of fiscal year
• March 31, 2024 (date) — end of prior fiscal year

FAQ

Risk Factors

• Lack of Revenue Generation [high — financial]: Regenerex Pharma, Inc. reported $0 in revenue for the fiscal year ended March 31, 2025, and the prior year. This indicates a complete absence of commercial sales, suggesting the company is in a pre-revenue or developmental stage with no current income-generating products or services.
• Dependence on Related Party Financing [high — financial]: The company relies on advances from its CEO and CFO, totaling $1,000 as of March 31, 2025, down from $10,000 in the prior year. Additionally, a $10,000 promissory note from a shareholder remains outstanding. This dependence on related parties for operating expenses and debt highlights a significant financial risk and potential lack of independent funding.
• Ongoing Operational Expenses Without Revenue [medium — operational]: Despite generating no revenue, the company continues to incur operational expenses, including a monthly plant facility lease of $1,000 and a monthly office lease of $1,000. These ongoing costs, without corresponding income, place a strain on the company's limited financial resources.

Industry Context

Regenerex Pharma, Inc. operates within the pharmaceutical preparations sector. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies typically focus on discovering, developing, and commercializing novel therapies, often requiring substantial capital investment and facing intense competition from established players and emerging biotechs.

Regulatory Implications

As a pharmaceutical company, Regenerex Pharma, Inc. is subject to stringent regulations from bodies like the FDA. While the filing doesn't detail specific regulatory progress, any development or commercialization efforts would require navigating complex approval processes, clinical trials, and post-market surveillance, posing significant compliance risks.

What Investors Should Do

1. Monitor progress on intellectual property development and commercialization strategy.
2. Assess the company's ability to secure non-related party funding.
3. Evaluate the burn rate relative to cash reserves and funding sources.

Key Dates

• 2021-11-15: Purchase of Intellectual Property — Acquisition of a significant asset, likely representing the core technology or product pipeline the company is developing.
• 2024-03-31: End of Fiscal Year 2024 — Reported $0 revenue and a net loss of $10,000, with $10,000 in CEO/CFO advances and a $10,000 shareholder promissory note outstanding.
• 2025-03-31: End of Fiscal Year 2025 — Reported $0 revenue and a net loss of $1,000, with $1,000 in CEO/CFO advances and a $10,000 shareholder promissory note outstanding, showing improved loss but continued lack of revenue.

Glossary

Intellectual Property

Intangible assets such as patents, trademarks, and copyrights that provide exclusive rights to use, sell, or manufacture an invention or product. (The company's primary asset, acquired for $100,000, indicates its focus on developing and commercializing proprietary technology.)

Promissory Note

A written promise by one party (the maker or issuer) to pay a specific sum of money to another party (the payee), either on demand or at a specified future date. (The outstanding $10,000 note from a shareholder represents a form of debt financing that the company needs to repay.)

Advances from CEO and CFO

Funds provided by the company's chief executive officer and chief financial officer to cover operating expenses, which are typically expected to be repaid. (Highlights the company's reliance on its top executives for short-term funding, indicating potential cash flow challenges.)

Year-Over-Year Comparison

For the fiscal year ended March 31, 2025, Regenerex Pharma, Inc. maintained zero revenue, consistent with the prior year. However, the company significantly improved its net loss, reducing it from $10,000 in FY2024 to $1,000 in FY2025. Reliance on related-party financing also decreased, with CEO/CFO advances dropping from $10,000 to $1,000, though the shareholder promissory note remained at $10,000. No new significant risks were introduced, but the existing risks of no revenue and related-party dependence persist.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on June 30, 2025 by CEO regarding REGENEREX PHARMA, INC. (RGPX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR